103 related articles for article (PubMed ID: 9793975)
21. Urinary screening tests for fetal Down syndrome: I. Fresh beta-core fragment.
Cole LA; Rinne KM; Mahajan SM; Oz UA; Shahabi S; Mahoney MJ; Bahado-Singh RO
Prenat Diagn; 1999 Apr; 19(4):340-50. PubMed ID: 10327140
[TBL] [Abstract][Full Text] [Related]
22. [Screening for Down syndrome using triple marker testing in the second trimester of pregnancy].
Lesin J; Skrablin S; Durić K; Suchanek E; Muzinić D; Kalafatić D; Kuvacić I; Zlopasa G; Plavec A
Lijec Vjesn; 2003; 125(3-4):55-60. PubMed ID: 12899094
[TBL] [Abstract][Full Text] [Related]
23. First-trimester maternal serum human thyroid-stimulating hormone in chromosomally normal and Down syndrome pregnancies.
Weinans MJ; Pratt JJ; de Wolf BT; Mantingh A
Prenat Diagn; 2001 Sep; 21(9):723-5. PubMed ID: 11559906
[TBL] [Abstract][Full Text] [Related]
24. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
Spencer K; Bindra R; Cacho AM; Nicolaides KH
Prenat Diagn; 2004 Mar; 24(3):169-73. PubMed ID: 15057947
[TBL] [Abstract][Full Text] [Related]
25. The impact of bias in MoM values on patient risk and screening performance for Down syndrome.
Nix B; Wright D; Baker A
Prenat Diagn; 2007 Sep; 27(9):840-5. PubMed ID: 17600858
[TBL] [Abstract][Full Text] [Related]
26. Comparison of 12 assays for detecting hCG and related molecules in urine samples from Down syndrome pregnancies.
Cole LA; Kellner LH; Isozaki T; Palomaki GE; Iles RK; Walker RP; Ozaki M; Canick JA
Prenat Diagn; 1997 Jul; 17(7):607-14. PubMed ID: 9249860
[TBL] [Abstract][Full Text] [Related]
27. Down syndrome maternal serum marker screening after 18 weeks' gestation.
Muller F; Dreux S; Oury JF; Luton D; Uzan S; Uzan M; Levardon M; Dommergues M
Prenat Diagn; 2002 Nov; 22(11):1001-4. PubMed ID: 12424764
[TBL] [Abstract][Full Text] [Related]
28. Second-trimester Down syndrome maternal serum screening in twin pregnancies: impact of chorionicity.
Muller F; Dreux S; Dupoizat H; Uzan S; Dubin MF; Oury JF; Dingeon B; Dommergues M
Prenat Diagn; 2003 Apr; 23(4):331-5. PubMed ID: 12673641
[TBL] [Abstract][Full Text] [Related]
29. Hyperglycosylated HCG expression in pregnancy: cellular origin and clinical applications.
Kovalevskaya G; Kakuma T; Schlatterer J; O'Connor JF
Mol Cell Endocrinol; 2007 Jan; 260-262():237-43. PubMed ID: 17092638
[TBL] [Abstract][Full Text] [Related]
30. Prenatal screening for Down syndrome: the problem of recurrent false-positives.
Wald NJ; Huttly WJ; Rudnicka AR
Prenat Diagn; 2004 May; 24(5):389-92. PubMed ID: 15164416
[TBL] [Abstract][Full Text] [Related]
31. Measures of urine concentration in maternal urine screening for Down syndrome.
Iles RK; Black A; Gunn LK; Sehmi IK; Cuckle HS; Chard T
Prenat Diagn; 1998 Oct; 18(10):1006-9. PubMed ID: 9826891
[TBL] [Abstract][Full Text] [Related]
32. Second-trimester levels of pregnancy-associated plasma protein-A and free beta-hCG in pregnancies with trisomy 13.
Spencer K; Crossley JA; Aitken DA; Nicolaides KH
Prenat Diagn; 2005 May; 25(5):358-61. PubMed ID: 15906423
[TBL] [Abstract][Full Text] [Related]
33. Integrated serum screening for Down syndrome in primary obstetric practice.
Knight GJ; Palomaki GE; Neveux LM; Smith DE; Kloza EM; Pulkkinen AJ; Williams J; Haddow JE
Prenat Diagn; 2005 Dec; 25(12):1162-7. PubMed ID: 16231402
[TBL] [Abstract][Full Text] [Related]
34. [Evaluating the applicability of MoM in second trimester maternal serum to screening for Down's syndrome in Jiangsu province].
Xu BY; Hu Y; Zhang CY; Zhang JW; Liu QL; Yue H; Ru T; Xu ZF; Zhu RF; Zhang Y; Zhong X; Wu QM
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):32-5. PubMed ID: 18247300
[TBL] [Abstract][Full Text] [Related]
35. Second trimester maternal serum hCG level in an Asian population: normal reference values by ultrasound dating.
Jou HJ; Shyu MK; Shih JC; Chang MY; Lim CC; Tzeng CY; Chen SM; Hsieh FJ
J Matern Fetal Med; 2000; 9(2):118-21. PubMed ID: 10902826
[TBL] [Abstract][Full Text] [Related]
36. Influence of maternal smoking on the birth prevalence of Down syndrome and on second trimester screening performance.
Rudnicka AR; Wald NJ; Huttly W; Hackshaw AK
Prenat Diagn; 2002 Oct; 22(10):893-7. PubMed ID: 12378572
[TBL] [Abstract][Full Text] [Related]
37. Effect on Down syndrome screening performance of adjusting for marker levels in a previous pregnancy.
Wald NJ; Barnes IM; Birger R; Huttly W
Prenat Diagn; 2006 Jun; 26(6):539-44. PubMed ID: 16634123
[TBL] [Abstract][Full Text] [Related]
38. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Nicolaides KH; Spencer K; Avgidou K; Faiola S; Falcon O
Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186
[TBL] [Abstract][Full Text] [Related]
39. Combined ultrasound biometry, serum markers and age for Down syndrome risk estimation.
Bahado-Singh RO; Oz AU; Gomez K; Hunter D; Copel J; Baumgarten A; Mahoney MJ
Ultrasound Obstet Gynecol; 2000 Mar; 15(3):199-204. PubMed ID: 10846774
[TBL] [Abstract][Full Text] [Related]
40. Triploidy identified through second-trimester serum screening.
Huang T; Alberman E; Wald N; Summers AM
Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
